Outlook Therapeutics(OTLK)
ISELIN, NJBiotechnology
Focus: Outlook Therapeutics is a public biotech company focused on developing biosimilars, with a concentrated pipeline centered on bevacizumab for ophthalmology indications including age-related macular degeneration. The company is pre-commercial with minimal revenue and operates as a mid-cap biotech with significant R&D intensity.
Profile data last refreshed 8h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Outlook Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Outlook Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Outlook Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Late-stage
5 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$1M
Pipeline & Clinical Trials
bevacizumab
Neovascular Age-related Macular DegenerationClinical Trials (1)
NCT06190093A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Phase 3Help build intelligence for Outlook Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.